All In Biotech

Drug Trial Radar · NCT06525272

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy

A Phase 1 Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT Administered Intrathoracically in Single and Multiple Doses in Patients With Pleurisy

Last checked: Nov 19, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Jul 2024

Primary completion

Jul 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Healthgen Biotechnology Corp.Industry
Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: To evaluate the safety and tolerability of single and multiple ascending doses of OsrhCT administered intrathoracically in patients with pleurisy, and to explore the DLT, MTD, and recommended effective dose of OsrhCT. Secondary Objectives: To evaluate the preliminary efficacy of single and multiple intrathoracic doses of OsrhCT. Population: Patients diagnosed with pleurisy requiring chest tube drainage. Investigational Products: Investigational Drug: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, stored at 2-8°C. Placebo: Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C. Study Design: The study comprises two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), both employing a multicenter, randomized, double-blind, and placebo-controlled design. Sample Size: A total of 72 subjects (both male and female) are expected to be enrolled in this trial, including 48 subjects for single-dose administration and 24 subjects for multiple-dose administration.

Conditions

  • Pleurisy

Interventions

  • Recombinant Human Chymotrypsin(OsrhCT)Drug

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.

  • Placebo for Recombinant Human Chymotrypsin(OsrhCT)Drug

    Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Outcome MeasuresTime frame: Single Ascending Dose (SAD) Study:7days;Multiple Ascending Dose (MAD) Study:30days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Chest Hospital

    Hefei, Anhui, China

  • Shenzhen Third People's Hospital

    Shenzhen, Guangdong, China

  • Wuhan Pulmonary Hospital

    Wuhan, Hubei, China

  • Changsha Central Hospital

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.